MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, December 29, 2017

Zinbryta Fails to Prevent RRMS from Worsening After Patient Gets Off Tysabri, Case Study Shows

DECEMBER 28, 2017    Patricia Inacio, PhD

Zinbryta (daclizumab) may not be the best follow-up therapy for relapsing–remitting multiple sclerosis patients who stop taking Tysabri (natalizumab) for safety reasons, a case study suggests.
An article on the 25-year-old patient’s case, titled “Disease reactivation after switching from natalizumab to daclizumab,” was published in the Journal of Neurology.
Discontining Biogen’s Tysabri leads to many patients’ disease worsening. The question doctors face is what treatment to prescribe after Tysabri. One possibility is Zinbryta.
The U.S. Food and Drug Administration and European Union approved it as therapy for active RRMS cases in 2016.  Biogen and AbbVie market the monoclonal antibody, which targets the CD25 protein that scientists have linked to MS.
Researchers studied the 25-year-old patient’s case for clues about whether Zinbryta could benefit MS patients who discontinue Tysabri.
...............................................................................

No comments: